In the present study, we demonstrated that the intravenous administration of AD-MSCs
FGF1 effectively diminishes apoptosis and inflammation of neuropathic pain that originates from a peripheral lesion. Following the peripheral nerve injury, a cascade of neuroinflammation-related events occurs in pain generation (
3,
16). Microglia are one of the first spinal cord cell types activated within the first hours of peripheral nerve injury, which continues for at least numerous months in experimental neuropathies. Microglial activation is characterized by the expression of Iba1 (
3). The release of IL-1β from spinal cells was enhanced following the responses to pathophysiological changes during neuropathic pain (
17). More pertinently in spinal cord neurons, IL-1β enhanced excitatory AMPA and NMDA-induced currents whilst suppressed GABA- and glycine-induced inhibitory currents (
18). Previous studies suggested that IL-1β induction of NMDA-currents may be via PK-C that phosphorylates NMDA subunits, NR1 and NR2B (
19). The inhibition of IL-1β signaling prevented transcriptional up-regulation of the COX-2 gene, which resulted in the reduction of mechanical hyperalgesia and normalization of pain sensitivity (
20). Matrix metalloproteinases (MMPs) are zinc-dependent proteins, have imperative roles in numerous proteolytic reactions, and are associated with different neurodegenerative disorders (
21). They degrade structural proteins of the extracellular and increase the amount of pro-inflammatory cytokines such as IL-1β (
22). In the context of neuropathic pain, elevated MMP-2 contributes to the development of neuropathic pain (
23). In accordance with previous literature (
21,
24), Iba1, IL-1β, and MMP-2 upregulation were seen on day 14 post-CCI. Administration of AD-MSCs and AD-MSCs
FGF1 significantly attenuated the contents of Iba1, IL-1β, and MMP-2, in the spinal cord of animals subjected to nerve injury. The corrective effect was greater in the AD-MSCs
FGF1 group. AD-MSCs are known to provide anti-inflammatory and anti-apoptotic by producing many growth factors, cytokines, and chemokines (
25). In a study by Sacerdote’s
et al., AD-MSc administration reduced the pro-inflammatory cytokine IL-1β. It increased the anti-inflammatory cytokine IL-10 in the injured nerve of the CCI rats. Besides, AD-MSc administration decreased the expression of inducible nitric oxide synthase in CCI animals’ spinal cord (
26). In a study conducted by Siniscalco
et al., injection of human MSCs to neuropathic mice led to decreased NP-like behaviors, mRNA levels of the pro-inflammatory interleukin IL-1β mouse gene, as well as astrocytic and microglial cell activations (
27). FGF1 induced the expression of T helper type 2 (T
h2) cytokine IL-4 and sequential upregulation of arginase-I
(Arg I) (
28). Arg I enhances the synthesis of polyamines that promote axonal regeneration and prevent cell death after injury (
29). Subsequently, the upregulation of Arg I leads to a decrement of the inflammatory response and neuropathic pain occurrence (
30). In a study conducted by Lin
et al., following cervical root transection, intercostal nerve grafts and FGF1 resulted in a decrement of microglial and IL-1β-positive astrocyte reactions in the spinal cord, along with a significant increase in arginase I expression (
30). The apoptotic processes appear and develop during the first few days after the induction of CCI. Subsequently, increased expression of anti-apoptotic Bcl-2 family genes may inhibit more neuronal loss. It could be associated with the own neuroprotection mechanisms of the nervous system (
31,
32). The results presented here show a significant elevation in the Bax/Bcl2 ratio and cleaved caspases 3 in CCI animals on day three post-surgery. Treatment with AD-MSCs and AD-MSCs
FGF1 leads to correction of the expressions of these factors. Again, the corrective effect was greater in the AD-MSCs
FGF1 group. Previously, we also showed that FGF1 therapy, along with stem cell transplantation, markedly diminished the CCI-induced DNA fragmentation and apoptosis in the spinal cord of CCI rats (
12). FGF1 is a differentiation and survival factor with multiple biological effects, such as angiogenesis, mitogenesis, and repair. It is highly expressed in the central and peripheral nervous systems (
33,
34). FGF1 is a repressed target gene of p53. The overexpression of FGF1 via increasing MDM2 (mouse double minute 2) expression leads to a decrement of pro-apoptotic and the anti-proliferative effects of p53 and Bax, a pro-apoptotic protein (
35). In the presence of DNA damages, FGF1 leads to a decrement in p53 stability activities and p53-dependent transactivation of the pro-apoptotic genes, such as puma, noxa, and caspases 3 (
34). In conclusion, the present study demonstrated that intravenous administration of AD-MSCs, transfected with the FGF1 gene, resulted in significant improvements in the spinal cord’s apoptosis and inflammation in a rat model of CCI, with greater efficacy than non-modified AD-MSCs and has vast potential for future studies.